Revvity, Inc. (RVTY) company profile
Close on Nov 17, 2026Market cap $16.49BP/E 70.4Yield 0.19%
About Revvity
Laboratory Analytical Instruments, SIC 3826
Revvity provides health science technologies, expertise, and integrated workflow solutions bridging research, clinical discovery, and medical care. The company operates across two core segments: Life Sciences and Diagnostics. Its Life Sciences division delivers reagents, automated liquid handlers, imaging instruments, detection platforms, and research informatics designed to optimize drug development, genomics, and cellular analysis. Its Diagnostics segment supplies analytical instruments, diagnostic assays, screening kits, and laboratory data management software specializing in prenatal and newborn screening, immunodiagnostics, and infectious disease detection. Revvity serves pharmaceutical and biotechnology corporations, contract research organizations, academic and governmental research institutions, hospitals, clinical laboratories, and healthcare professionals.
Headquartered in Waltham, Massachusetts, the company conducts its commercial operations globally, marketing products and services across more than 160 countries. Its operational infrastructure includes a worldwide network of specialized genomic testing laboratories located in the United States, China, the United Kingdom, and India. Revvity maintains an international workforce of approximately 11,000 employees supporting its healthcare and diagnostic capabilities.
Summary of the business section of Revvity's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Revvity, Inc.
- Founded
- 1937
- Headquarters
- Waltham, MA
- Address
- 77 4th Avenue 02451
- Phone
- (781) 663-6900
- Website
- revvity.com
- Employees
- 11,000, Dec 28, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Massachusetts
- Fiscal year ends
- December 29
- Auditor
- DELOITTE & TOUCHE LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RVTY
- Former tickers
- PKI until Aug 1, 2023
- Exchange
- NYSE
- Shares outstanding
- 112M, Aug 6, 2026
- Public float
- $11.30B, Jun 28, 2024
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 4, 2001; 2-for-1, May 11, 1992; 2-for-1, Feb 2, 1982; 2-for-1, Feb 4, 1980
- SEC CIK
- 31791
- CUSIP
- 714046109
- ISIN
- US7140461093
- FIGI
- BBG000FXW512
- Share class FIGI
- BBG001SBKS35
- LEI
- 549300IKL1SDPFI7N655
- EIN
- 04-2052042
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Prahlad R. Singh | Please See Remarks, Director | 159,895 |
| Anita Gonzales | VP and CAO | 7,117 |
| Maxwell Krakowiak | Please See Remarks | 14,781 |
| Tajinder S. Vohra | Please See Remarks | 18,818 |
| Joel S. Goldberg | Please See Remarks | 105,223 |
| Miriame Victor | Please See Remarks | 18,122 |
| Alexis P. Michas | Director | 71,265 |
| Michael A. Klobuchar | Director | 6,103 |
| Michelle McMurry-Heath | Director | 5,248 |
| Samuel R. Chapin | Director | 22,676 |
| Peter Barrett | Director | 28,293 |
| Sophie V. Vandebroek | Director | 6,103 |
| Frank Witney | Director | 22,089 |
| Michel Vounatsos | Director | 12,712 |
| Pascale Witz | Director | 14,720 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.81M | $5.80M | $3.94M | $68 | $105 |
| FY2024 | $11.93M | $11.46M | $2.85M | $79 | $100 |
| FY2023 | $9.13M | $3.65M | $2.22M | $77 | $104 |
| FY2022 | $10.58M | $1.81M | $2.07M | $98 | $107 |
| FY2021 | $9.66M | $22.36M | $2.40M | $140 | $139 |
| FY2020 | $9.02M | $17.61M | $2.95M | $148 | $132 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Prahlad R. Singh Chief Executive Officer | $1.13M | $7.69M | $2.56M | $2.39M | $40.73K | $13.81M | +16% |
| Maxwell Krakowiak Senior Vice President and Chief Financial Officer | $550.58K | $2.10M | $2.10M | $598.92K | $27.62K | $5.37M | +66% |
| Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary | $564.62K | $1.82M | $604.24K | $636.12K | $46.64K | $3.67M | +8% |
| Miriame Victor Senior Vice President and Chief Commercial Officer | $503.27K | $1.53M | $1.53M | $509.08K | $26.74K | $4.10M | +65% |
| Tajinder S. Vohra Senior Vice President, Global Operations | $489.62K | $1.21M | $401.28K | $515.59K | $26.23K | $2.64M | +14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 28, 2025, we employed approximately 11,000 employees on a worldwide basis.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?